11 medical institutions, mainly in Tokyo, were ordered to stop cord-blood therapy of cancer or aging because they had not requested permission from the designated MHLW committee. The cord blood was obtained from undisclosed cell-processing facilities and no provision plans were submitted.

Nikkei Biotech news release, June 29, 2017